Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corus Pharma Inc.

Division of Gilead Sciences Inc.

Latest From Corus Pharma Inc.

Deal Statistics Quarterly, Q4 2006

We present another installment of our quarterly review of dealmaking-for October-December 2006. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
BioPharmaceutical Medical Device

IPO Failures Can Set Up Biotech Successes

Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.
BioPharmaceutical Business Strategies

European Consolidation: Serious Competition for Big Pharma?

Merck KGAA surprised observers when it announced the €10.6 billion takeover of Europe's biggest biotech, Serono. There was more consolidation to come. That same day, the Danish pharmaceutical group Nycomed Group said it would acquire Altana Pharma for about €4.5 billion in cash. Only a couple days later, UCB SA entered the fray with the acquisition of Schwarz Pharma AG for €4.2 billion in cash and stock. Can these bulked up companies present serious competition for Big Pharma on the licensing front?
BioPharmaceutical Europe

Biotech Financing Roundup: Where the Money's At

There's a perceived transatlantic divide when it comes to biotechnology financing. European firms, the conventional wisdom goes, lack VC the support of their North American counterparts and thus are at an inherent disadvantage. But an analysis of 2004's VC financing trends shows that on average, European biotechs have pulled in respectable Series A and Series B rounds--later stage financing is another story.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • William Baker, PhD, VP, Research
    Jonathan P Mow, VP, Commercial & Bus. Dev.
  • Contact Info
  • Corus Pharma Inc.
    Phone: (206) 728-5090
    2025 1st Ave., Ste. 800
    Seattle, WA 98121